October 2024 - Portal presented the poster "Addressing the Challenges of Highly Viscous Formulations Using a Needle-Free Technology" at the The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona.
October 2024 - Portal recently shared its latest research at The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona. The poster "Addressing the Challenges of Highly Viscous Formulations
Using a Needle-Free Technology" showed ex-vivo testing results which demonstrated PRIME Needle-Free injector can eject consistently and faster than a needle and syringe, while depositing the injectate at a similar depth in the subcutaneous space.
The ability for PRIME NF to eject high viscosity fluids consistently and rapidly could open the doors for new therapies as well as increase patient access to a more agreeable method of drug delivery. Having a needle-free system not only quells the common fear of needles but also boasts faster and more reliable injection times than a mechanical autoinjector. The findings of this study hint at the prospect of pushing beyond the constraints imposed by current needle-based injection devices.
March 23, 2021 - Cambridge, MA The Sumaira Foundation for NMO (TSF) and Portal Instruments are pleased to announce their partnership. Portal Instruments and TSF share a joint vision of creating a better experience and improved treatment options for patients diagnosed with NMOSD.
November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
Today Portal Instruments announced the signing of a multi-million-dollar development agreement with a leading biotech company to advance its large-volume, reusable autoinjector, PRIME NEXUS™, toward clinical readiness in Q1 2027.
Please fill out the details below and we will get back to you shortly.